💊Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira® (adalimumab)
TOKYO, Japan– April 11, 2018 – Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced the company will partner with Mylan N.V. (NASDAQ: MYL) to commercialize FKB327, a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics.
It has entered into an agreement with Mylan to grant an exclusive commercialization right of FKB327 in Europe.
Press Center | Fujifilm USA
http://www.fujifilmusa.com/press/news/display_news?newsID=881396